{"url":"https://newsforagent.com/news/2026-10-20/alcon-acquires-neurotech-pharmaceuticals","markdown_url":"https://newsforagent.com/news/2026-10-20/alcon-acquires-neurotech-pharmaceuticals.md","title":"Alcon Buys Neurotech for $550 Million, Adding MacTel Therapy","headline":"Alcon Acquires Neurotech Pharmaceuticals for $550 Million, Adding FDA-Approved ENCELTO","description":"Alcon acquired Neurotech Pharmaceuticals for $550 million, adding ENCELTO, the only FDA-approved treatment for adult MacTel Type 2, with 2027 EPS dilution.","section":"Mergers & Acquisitions","published_at":"2026-10-20T21:04:53+00:00","modified_at":"2026-10-20T21:04:53+00:00","author":"News Desk","key_takeaways":["Alcon acquired Neurotech Pharmaceuticals for $550 million, adding ENCELTO, the only FDA-approved treatment for adult MacTel Type 2.","Alcon expects slight core EPS dilution in 2027, with accretion thereafter, and modest net sales uplift from the acquisition.","The U.S. MacTel patient population is approximately 25,000, with 2,000 to 3,000 new diagnoses per year."],"companies":[{"name":"Alcon","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0003le2/alcon","website":"http://www.alcon.com"},{"name":"Neurotech","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0003s1k/neurotech","website":"https://www.neurotechpharmaceuticals.com"}],"source":{"publisher":"TradingView","title":"Alcon (ALC) Buys Neurotech for $550M, Adding FDA-Approved MacTel Therapy","url":"https://www.tradingview.com/news/tradingview:d58dbcc4f0479:0-alcon-alc-buys-neurotech-for-550m-adding-fda-approved-mactel-therapy/"},"other_sources":[],"tags":["Mergers & Acquisitions","Alcon","Neurotech"],"body_markdown":"[Alcon](https://akta.pro/company-profiles/0003le2/alcon) acquired Neurotech Pharmaceuticals for $550 million, adding ENCELTO, the only FDA-approved treatment for adult macular telangiectasia type 2. [TradingView](https://www.tradingview.com/news/tradingview:d58dbcc4f0479:0-alcon-alc-buys-neurotech-for-550m-adding-fda-approved-mactel-therapy/) reported the deal, which Alcon expects to cause slight core EPS dilution in 2027, with accretion thereafter.\n\n## Alcon's $550 Million Neurotech Deal\n\nAlcon is the largest global eye care device company, operating Surgical and Vision Care segments and serving surgeons and patients in more than 140 countries. [Neurotech](https://akta.pro/company-profiles/0003s1k/neurotech) developed ENCELTO, an encapsulated cell therapy implant approved by the FDA as the first treatment for adults with idiopathic macular telangiectasia type 2, according to CGTLive.\n\nAlcon expects modest net sales uplift from the acquisition and potential milestone payments contingent on commercial success. The U.S. MacTel patient population is approximately 25,000, with 2,000 to 3,000 new diagnoses per year. Alcon said the deal extends its retina portfolio with a commercial, orphan therapy.\n\n## Alcon's Recent Deal History\n\nAccording to [akta.pro company records](https://akta.pro/company-data), Alcon and LENSAR terminated their merger agreement in March 2026 after the FTC determined the deal would harm competition in the femtosecond laser-assisted cataract surgery market by combining the two dominant players. Alcon acquired LumiThera in July 2025, adding the Valeda photobiomodulation device for treating early and intermediate dry age-related macular degeneration and entering a new AMD therapy category. Alcon reported 2025 net sales of $10.3 billion and Q1 2026 sales of $2.7 billion.\n\n## Alcon's Product Approvals Before the Deal\n\nThe FDA approved Alcon's BRYTLY Redness Reliever Eye Drops in October 2026, which reduce redness in one minute and last up to 12 hours, Stock Titan reported. Alcon launched Systane PRO Preservative-Free in Canada in September 2026, a triple-action preservative-free eye drop for dry eye providing up to 12 hours of symptom relief. Alcon announced the initial commercial launch of its UNITY M surgical microscope in the U.S. and Japan in September 2026, with Europe to follow.\n\n## Neurotech's ENCELTO Approval\n\nNeurotech announced in August 2026 that the FDA granted priority review for its Biologic License Application for NT-501, a therapy for MacTel, with a PDUFA goal date of December 17, 2024, Ophthalmology Times reported. The FDA approved Encelto (revakinagene taroretcel-lwey) as the first treatment for adults with idiopathic macular telangiectasia type 2, with the encapsulated cell therapy implant expected to become available in the United States in June 2025.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}